Intech Investment Management LLC Increases Stock Holdings in TG Therapeutics, Inc. $TGTX

Key Points

• Intech Investment Management LLC increased its shares in TG Therapeutics, Inc. by 20.5%, bringing its total to 86,527 shares, valued at approximately $3.4 million.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a price objective of $37.00, while the stock currently has an average consensus target price of $46.25.
• Insider activity was noted as Director Sagar Lonial sold over 20,000 shares, decreasing his position by 18.15% following the transaction.

Intech Investment Management LLC lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 20.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 86,527 shares of the biopharmaceutical company's stock after purchasing an additional 14,694 shares during the quarter. Intech Investment Management LLC owned 0.05% of TG Therapeutics worth $3,412,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. CWM LLC grew its holdings in TG Therapeutics by 16.2% during the first quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock worth $82,000 after buying an additional 290 shares in the last quarter. Golden State Wealth Management LLC boosted its holdings in TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 433 shares during the period. Smartleaf Asset Management LLC lifted its holdings in TG Therapeutics by 26.8% in the 1st quarter. Smartleaf Asset Management LLC now owns 2,416 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 511 shares during the period. Xponance Inc. lifted its holdings in TG Therapeutics by 5.3% in the 1st quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company's stock worth $428,000 after buying an additional 543 shares during the period. Finally, Choreo LLC lifted its stake in shares of TG Therapeutics by 7.6% in the 1st quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company's stock valued at $337,000 after purchasing an additional 602 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. B. Riley lifted their target price on TG Therapeutics from $53.00 to $55.00 and gave the company a "buy" rating in a research report on Wednesday. The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a report on Thursday, July 10th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $48.00.

Insiders Place Their Bets

In related news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the sale, the director directly owned 94,061 shares of the company's stock, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.64% of the stock is owned by company insiders.

TG Therapeutics Stock Up 1.8%

Shares of TG Therapeutics stock traded up $0.57 during trading on Thursday, reaching $32.61. The company had a trading volume of 1,684,017 shares, compared to its average volume of 2,002,512. The company has a market cap of $5.17 billion, a price-to-earnings ratio of 88.14 and a beta of 1.88. TG Therapeutics, Inc. has a fifty-two week low of $21.16 and a fifty-two week high of $46.48. The firm's fifty day moving average is $32.01 and its 200-day moving average is $35.67. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business had revenue of $141.15 million for the quarter, compared to the consensus estimate of $147.76 million. During the same quarter in the previous year, the business posted $0.04 earnings per share. The company's quarterly revenue was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. On average, analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.